AU2010319349B2 - Crystalline forms of neurotrophin mimetic compounds and their salts - Google Patents

Crystalline forms of neurotrophin mimetic compounds and their salts Download PDF

Info

Publication number
AU2010319349B2
AU2010319349B2 AU2010319349A AU2010319349A AU2010319349B2 AU 2010319349 B2 AU2010319349 B2 AU 2010319349B2 AU 2010319349 A AU2010319349 A AU 2010319349A AU 2010319349 A AU2010319349 A AU 2010319349A AU 2010319349 B2 AU2010319349 B2 AU 2010319349B2
Authority
AU
Australia
Prior art keywords
amino
pentanamide
methyl
morpholinoethyl
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010319349A
Other languages
English (en)
Other versions
AU2010319349A1 (en
Inventor
Frank M. Longo
Rajgopal Munigeti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmatrophix Inc
Original Assignee
Pharmatrophix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmatrophix Inc filed Critical Pharmatrophix Inc
Publication of AU2010319349A1 publication Critical patent/AU2010319349A1/en
Application granted granted Critical
Publication of AU2010319349B2 publication Critical patent/AU2010319349B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2010319349A 2009-11-12 2010-11-12 Crystalline forms of neurotrophin mimetic compounds and their salts Ceased AU2010319349B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26067109P 2009-11-12 2009-11-12
US61/260,671 2009-11-12
US29427910P 2010-01-12 2010-01-12
US61/294,279 2010-01-12
US35079710P 2010-06-02 2010-06-02
US61/350,797 2010-06-02
PCT/US2010/056537 WO2011060262A1 (en) 2009-11-12 2010-11-12 Crystalline forms of neurotrophin mimetic compounds and their salts

Publications (2)

Publication Number Publication Date
AU2010319349A1 AU2010319349A1 (en) 2012-07-05
AU2010319349B2 true AU2010319349B2 (en) 2015-07-16

Family

ID=43992064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010319349A Ceased AU2010319349B2 (en) 2009-11-12 2010-11-12 Crystalline forms of neurotrophin mimetic compounds and their salts

Country Status (9)

Country Link
US (3) US9271986B2 (enExample)
EP (2) EP2498782B1 (enExample)
JP (3) JP5863663B2 (enExample)
CN (3) CN108383804A (enExample)
AU (1) AU2010319349B2 (enExample)
CA (2) CA2780940C (enExample)
ES (1) ES2712752T3 (enExample)
IN (1) IN2012DN05142A (enExample)
WO (1) WO2011060262A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CA2780940C (en) 2009-11-12 2021-08-31 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
AU2013323416A1 (en) * 2012-09-27 2015-04-16 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
WO2016196804A1 (en) * 2015-06-04 2016-12-08 Balchem Corporation Hydration control for choline salts
US11215532B2 (en) 2020-05-04 2022-01-04 Ford Global Technologies, Llc Methods and systems for exhaust gas recirculation system diagnostics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246072A1 (en) * 2005-04-15 2006-11-02 University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3541130A (en) 1967-02-06 1970-11-17 Boehringer Sohn Ingelheim 1-(cyanophenoxy)-2-hydroxy-3-tert.-butylamine propanes
US4613676A (en) 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
US4743607A (en) 1987-05-29 1988-05-10 Merrell Dow Pharmaceuticals Inc. Cardiotonic tricyclic imidazolones
JPH04503205A (ja) 1988-05-02 1992-06-11 ナフッチィ，エヌ，エリック 神経学的活性化合物
US5028622A (en) 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5321029A (en) 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
CA2010531A1 (en) * 1989-03-06 1990-09-06 Werner Neidhart Amino acid derivatives
DE59205565D1 (de) 1991-10-07 1996-04-11 Hoechst Ag Carbonsäureester-Schutzgruppen, ein Verfahren zu ihrer Herstellung, ihre Kopplung an eine funktionelle Gruppe sowie ihre Verwendung
US5608067A (en) 1993-12-09 1997-03-04 Afonso; Adriano 4-substituted pyrazoloquinoline derivatives
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
JPH08119922A (ja) 1994-10-21 1996-05-14 Torii Yakuhin Kk ｏ−ピバロイル−チロシン誘導体
AU4117396A (en) * 1994-11-29 1996-06-19 Novartis Ag Morpholinoethylamide derivatives
JPH1081661A (ja) 1995-10-23 1998-03-31 Sankyo Co Ltd ヒドロキサム酸誘導体
EP0890105B1 (en) 1996-03-29 2006-11-22 The Trustees Of Boston University Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
US5958875A (en) 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
WO1997042168A1 (en) 1996-05-06 1997-11-13 Zeneca Limited Thio derivatives of hydroxamic acids
GB9613547D0 (en) 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
GB9715962D0 (en) 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
PT968206E (pt) 1997-02-19 2007-02-28 Pharmacopeia Inc Derivados n-heterocíclicos como inibidores de nos
FR2762315B1 (fr) 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
AU7698998A (en) 1997-05-30 1998-12-30 Neurex Corporation Substituted peptidylamine calcium channel blockers
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
EP1143960A2 (en) 1998-11-06 2001-10-17 Roche Diagnostics GmbH Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
AU2180600A (en) 1998-12-18 2000-07-12 Warner-Lambert Company Non-peptide nk1 receptors antagonists
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
DE19939910A1 (de) 1999-08-23 2001-03-01 Morphochem Ag Neue Verbindungen, die Tryptase-Aktivität hemmen
MXPA02002578A (es) 1999-09-08 2002-10-23 Guilford Pharm Inc Compuestos de union a ciclofilina no peptidicos, y su uso.
CA2393757C (en) 1999-12-08 2009-04-07 Teijin Limited Cycloamine ccr5 receptor antagonists
ATE340571T1 (de) 2000-01-18 2006-10-15 Univ Mcgill Pharmazeutische zubereitungen enthaltend beta- turn peptidomimetische zyklische substanzen
AR028606A1 (es) 2000-05-24 2003-05-14 Smithkline Beecham Corp Nuevos inhibidores de mmp-2/mmp-9
US6699989B1 (en) 2000-08-28 2004-03-02 B. Vithal Shetty Antiviral and antimicrobial guanidine or biguanidine derivatives
WO2002048660A1 (en) * 2000-12-13 2002-06-20 Spelman College Multiplex coherent raman spectroscopy detector and method
HRP20040069A2 (en) 2001-07-11 2005-02-28 Elan Pharmaceuticals Pharmacia & Upjohn Company N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
US20040248984A1 (en) 2001-08-29 2004-12-09 Josef Krieglstein Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
AU2002335824A1 (en) 2001-10-12 2003-04-22 Case Western Reserve University Neuronal regeneration
EP1453789A2 (en) 2001-11-08 2004-09-08 Elan Pharmaceuticals, Inc. N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives
MXPA04010921A (es) * 2002-05-03 2005-05-27 Israel Inst Biolog Res Metodos y composiciones para el tratamietno de trastornos del sistema nervioso central y periferico y compuestos novedosos utiles para los mismos.
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
EP1553964A4 (en) 2002-09-25 2009-08-12 Georgia Tech Res Inst KETOAMID INHIBITORS IN CHRONIC NERVE DISEASES
US20040077635A1 (en) 2002-10-02 2004-04-22 Qiao Jennifer X. Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor Xa inhibitors
US20040186044A1 (en) 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
US20050154011A1 (en) 2003-02-20 2005-07-14 The Procter & Gamble Company Tetrahydroisoquinolnyl sulfamic acids
GB0304433D0 (en) 2003-02-27 2003-04-02 Xceleron Ltd Improvements relating to chemical libraries
US7202269B2 (en) 2003-10-30 2007-04-10 Janssen Pharmaceutica N.V. GlyT2 modulators
EP1689721B1 (en) 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
WO2005070407A1 (en) 2004-01-21 2005-08-04 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
WO2005095327A1 (ja) 2004-03-31 2005-10-13 Ajinomoto Co., Inc. アニリン誘導体
AU2005261487A1 (en) 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
JP4194540B2 (ja) 2004-07-27 2008-12-10 キヤノン株式会社 画像形成装置
US20110230479A1 (en) 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
US8686045B2 (en) 2005-06-08 2014-04-01 The University Of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
TW201900217A (zh) 2005-12-22 2019-01-01 美商海卓勒生物科學公司 用於調節ｔｒｐａ１功能之化合物
WO2008107365A1 (en) 2007-03-02 2008-09-12 Medivir Ab New compounds
JP2012519703A (ja) 2009-03-06 2012-08-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ニューロトロフィン・ミメティック及びその使用
CA2780940C (en) 2009-11-12 2021-08-31 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
WO2011066544A2 (en) 2009-11-30 2011-06-03 Pharmatrophix, Inc. Deuterated compounds useful for treating neurodegenerative diseases
AU2013323416A1 (en) 2012-09-27 2015-04-16 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246072A1 (en) * 2005-04-15 2006-11-02 University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D2 : MASSA, S. M. et al., "Small, Nonpeptide p75NTR Ligands Induces Survival Signaling and Inhibit proNGF-Induced Death.", The Journal of Neuroscience, 2006, Vol. 26, pages 5288-5300 *

Also Published As

Publication number Publication date
JP2013510874A (ja) 2013-03-28
CN108383804A (zh) 2018-08-10
EP2498782A1 (en) 2012-09-19
US20180037559A1 (en) 2018-02-08
AU2010319349A1 (en) 2012-07-05
CN102740856B (zh) 2015-02-18
EP3470402B1 (en) 2021-01-06
CN104761515A (zh) 2015-07-08
JP5863663B2 (ja) 2016-02-16
ES2712752T3 (es) 2019-05-14
US9271986B2 (en) 2016-03-01
IN2012DN05142A (enExample) 2015-10-23
US20130005731A1 (en) 2013-01-03
HK1212970A1 (zh) 2016-06-24
US20160176832A1 (en) 2016-06-23
CN102740856A (zh) 2012-10-17
EP2498782B1 (en) 2019-01-09
CA2780940A1 (en) 2011-05-19
CN104761515B (zh) 2018-03-09
EP2498782A4 (en) 2014-03-12
JP2018115218A (ja) 2018-07-26
JP6657294B2 (ja) 2020-03-04
US10532988B2 (en) 2020-01-14
CA2780940C (en) 2021-08-31
EP3470402A1 (en) 2019-04-17
CA3125909A1 (en) 2011-05-19
WO2011060262A1 (en) 2011-05-19
CA3125909C (en) 2023-10-31
JP2016020380A (ja) 2016-02-04

Similar Documents

Publication Publication Date Title
US10532988B2 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
AU2021203085B2 (en) Crystalline forms of quinolone analogs and their salts
US20220162177A1 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
US9884833B2 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
US9957282B2 (en) Crystalline forms of quinolone analogs and their salts
HK1212970B (en) Crystalline forms of neurotrophin mimetic compounds and their salts
HK1177152B (en) Crystalline forms of neurotrophin mimetic compounds and their salts
HK1177152A1 (en) Crystalline forms of neurotrophin mimetic compounds and their salts

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired